G. Augello, M. R. Emma, A. Cusimano, A. Azzolina, S. Mongiovì et al., Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma, International Journal of Cancer, vol.144, issue.10, pp.2613-2624, 2018.

Y. Bak, H. J. Shin, I. S. Bak, D. Y. Yoon, and D. Y. Yu, Hepatitis B virus X promotes hepatocellular carcinoma development via nuclear protein 1 pathway, Biochemical and Biophysical Research Communications, vol.466, issue.4, pp.676-681, 2015.

C. Botto, G. Augello, E. Amore, M. R. Emma, A. Azzolina et al., Cationic Solid Lipid Nanoparticles as Non Viral Vectors for the Inhibition of Hepatocellular Carcinoma Growth by RNA Interference, Journal of Biomedical Nanotechnology, vol.14, issue.5, pp.1009-1016, 2018.

J. Bruix, L. G. Da-fonseca, and M. Reig, Insights into the success and failure of systemic therapy for hepatocellular carcinoma, Nature Reviews Gastroenterology & Hepatology, vol.16, issue.10, pp.617-630, 2019.

J. Bruix, M. Sherman, J. M. Llovet, M. Beaugrand, R. Lencioni et al., Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference, Journal of Hepatology, vol.35, issue.3, pp.421-430, 2001.

C. Y. Chen, S. M. Wu, Y. H. Lin, H. C. Chi, S. H. Lin et al., Induction of nuclear protein-1 by thyroid hormone enhances platelet-derived growth factor A mediated angiogenesis in liver cancer, Theranostics, vol.9, issue.8, pp.2361-2379, 2019.

M. H. Chen, W. L. Yang, K. T. Lin, C. H. Liu, Y. H. Liu et al., Gene Expression-Based Chemical Genomics Identifies Potential Therapeutic Drugs in Hepatocellular Carcinoma, PLoS ONE, vol.6, issue.11, p.e27186, 2011.

A. Conti, K. Dreval, V. Tryndyak, O. E. Orisakwe, S. A. Ross et al., Inhibition of the cell death pathway in nonalcoholic steatohepatitis (NASH)-Related hepatocarcinogenesis is associated with histone H4 lysine 16 deacetylation, Mol. Canc. Res. : MCR, vol.15, pp.1163-1172, 2017.

M. R. Emma, J. L. Iovanna, D. Bachvarov, R. Puleio, G. R. Loria et al., NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance, Cell Death & Disease, vol.7, issue.6, pp.e2269-e2269, 2016.

A. Forner, J. M. Llovet, and J. Bruix, Hepatocellular carcinoma, The Lancet, vol.379, issue.9822, pp.1245-1255, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01134844

H. Huang, Y. Zhang, X. Wang, X. Zhou, S. Li et al., Nuclear protein 1 knockdown inhibits proliferation and migration of HepG2 cells], Xi bao yu fen zi mian yi xue, za zhi = Chinese journal of cellular and molecular immunology, vol.31, pp.782-786, 2015.

Y. Ji, Z. Wang, H. Chen, L. Zhang, F. Zhuo et al., Serum from Chronic Hepatitis B Patients Promotes Growth and Proliferation via the IGF-II/IGF-IR/MEK/ERK Signaling Pathway in Hepatocellular Carcinoma Cells, Cellular Physiology and Biochemistry, vol.47, issue.1, pp.39-53, 2018.

Y. K. Lee, B. A. Jee, S. M. Kwon, Y. S. Yoon, W. G. Xu et al., Identification of a mitochondrial defect gene signature revealsNUPR1as a key regulator of liver cancer progression, Hepatology, vol.62, issue.4, pp.1174-1189, 2015.

Y. K. Lee, H. G. Woo, and G. Yoon, Mitochondrial defect-responsive gene signature in liver-cancer progression, BMB Reports, vol.48, issue.11, pp.597-598, 2015.

J. L. Neira, J. Bintz, M. Arruebo, B. Rizzuti, T. Bonacci et al., Identification of a Drug Targeting an Intrinsically Disordered Protein Involved in Pancreatic Adenocarcinoma, Scientific Reports, vol.7, issue.1, p.39732, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01788020

P. Nicotera and G. Melino, Regulation of the apoptosis?necrosis switch, Oncogene, vol.23, issue.16, pp.2757-2765, 2004.

N. Pedrola, L. Devis, M. Llauradó, I. Campoy, E. Martinez-garcia et al., Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion, Clinical & Experimental Metastasis, vol.32, issue.5, pp.467-478, 2015.

E. Colas, J. Reventos, and A. Ruiz, Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion, Clin. Exp. Metastasis, vol.32, pp.467-478, 2015.

P. Santofimia-castaño, B. Rizzuti, Y. Xia, O. Abian, L. Peng et al., Designing and repurposing drugs to target intrinsically disordered proteins for cancer treatment: using NUPR1 as a paradigm, Molecular & Cellular Oncology, vol.6, issue.5, p.e1612678, 2019.

P. Santofimia-castaño, Y. Xia, W. Lan, Z. Zhou, C. Huang et al., Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis, Journal of Clinical Investigation, vol.129, issue.6, pp.2500-2513, 2019.

S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet et al., Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling, Molecular Cancer Therapeutics, vol.7, issue.10, pp.3129-3140, 2008.

J. D. Yang, P. Hainaut, G. J. Gores, A. Amadou, A. Plymoth et al., A global view of hepatocellular carcinoma: trends, risk, prevention and management, Nature Reviews Gastroenterology & Hepatology, vol.16, issue.10, pp.589-604, 2019.